{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "79ffa128-a4b9-490a-a622-49393f147b1e",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "ffedc466-4b8e-4d85-a17a-3f701041cc6a",
          "code": {
            "id": "c4288c10-5d9a-4430-a221-a3b20bcf7b81",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "75fcca27-fe46-4b3f-a485-d5573e75acd4",
            "type": {
              "id": "8ec8837c-dba1-4613-b4cd-6cd2a670d262",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Added editorial changes throughout the document to improve clarity and to correct typographic errors. Revised Protocol Summary to reflect modifications. Expanded the age range for Cohort 1 to include subjects 65 years of age and older and added flexibility to clinical assessment wording. Updated study size and power information for Cohort 1 and clarified immunogenicity bridging analysis for Cohorts 2 and 3.",
        "effectiveDate": "2018-09-25",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "1"
      },
      {
        "id": "amend_2",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "1e189dcc-1568-4b9d-a715-105ea6ee891f",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "df0bbbda-c693-4caa-a226-844b747e0146",
          "code": {
            "id": "1e773425-eaf2-4130-b28f-8a39eeb6a98f",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "4f1838fe-27d8-47c4-b94f-bb2eded5c3ee",
            "type": {
              "id": "4c6ede1c-06ed-4a01-8f1e-51e0de44305b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Section 1.3: Added benefit-risk assessment (country specific-amendment, required for Sweden by the Swedish Medical Products Agency [MPA]). European Clinical Trials Database (EudraCT) Number: Updated to 2018-004279-11.",
        "effectiveDate": "2019-02-11",
        "reasonIds": [
          "ar_2_1"
        ],
        "previousVersion": "1",
        "newVersion": "2"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "Sweden",
        "instanceType": "Country",
        "code": "SE"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 2,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2"
      ],
      "regions": [
        "North America",
        "Europe"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "1",
        "effectiveDate": "2018-09-25",
        "summary": "Added editorial changes throughout the document to improve clarity and to correct typographic errors. Revised Protocol Summary to reflect modifications. Expanded the age range for Cohort 1 to include subjects 65 years of age and older and added flexibility to clinical assessment wording. Updated study size and power information for Cohort 1 and clarified immunogenicity bridging analysis for Cohorts 2 and 3.",
        "previousVersion": "Original Protocol",
        "newVersion": "1",
        "reasons": [
          "Scientific",
          "Operational",
          "Administrative"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2019-02-11",
        "summary": "Section 1.3: Added benefit-risk assessment (country specific-amendment, required for Sweden by the Swedish Medical Products Agency [MPA]). European Clinical Trials Database (EudraCT) Number: Updated to 2018-004279-11.",
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": [
          "Regulatory"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Sweden",
          "code": "SE"
        }
      ],
      "regions": [
        "North America",
        "Europe"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}